TTNP vs. BCDA, BBI, MBOT, AIM, PMCB, EVAX, IKT, SNTI, APTO, and COEP
Should you be buying Titan Pharmaceuticals stock or one of its competitors? The main competitors of Titan Pharmaceuticals include BioCardia (BCDA), Brickell Biotech (BBI), Microbot Medical (MBOT), AIM ImmunoTech (AIM), PharmaCyte Biotech (PMCB), Evaxion Biotech A/S (EVAX), Inhibikase Therapeutics (IKT), Senti Biosciences (SNTI), Aptose Biosciences (APTO), and Coeptis Therapeutics (COEP). These companies are all part of the "medical" sector.
BioCardia (NASDAQ:BCDA) and Titan Pharmaceuticals (NASDAQ:TTNP) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, community ranking, valuation, analyst recommendations, media sentiment, risk, earnings and profitability.
In the previous week, BioCardia had 2 more articles in the media than Titan Pharmaceuticals. MarketBeat recorded 4 mentions for BioCardia and 2 mentions for Titan Pharmaceuticals. BioCardia's average media sentiment score of 0.96 beat Titan Pharmaceuticals' score of 0.72 indicating that Titan Pharmaceuticals is being referred to more favorably in the news media.
Titan Pharmaceuticals has lower revenue, but higher earnings than BioCardia.
Titan Pharmaceuticals has a net margin of 0.00% compared to Titan Pharmaceuticals' net margin of -2,208.76%. BioCardia's return on equity of -99.96% beat Titan Pharmaceuticals' return on equity.
BioCardia presently has a consensus target price of $4.00, suggesting a potential upside of 33.78%. Given Titan Pharmaceuticals' higher possible upside, analysts plainly believe BioCardia is more favorable than Titan Pharmaceuticals.
BioCardia has a beta of 1.37, indicating that its stock price is 37% more volatile than the S&P 500. Comparatively, Titan Pharmaceuticals has a beta of 1.17, indicating that its stock price is 17% more volatile than the S&P 500.
Titan Pharmaceuticals received 323 more outperform votes than BioCardia when rated by MarketBeat users. Likewise, 56.21% of users gave Titan Pharmaceuticals an outperform vote while only 52.17% of users gave BioCardia an outperform vote.
20.6% of BioCardia shares are held by institutional investors. Comparatively, 31.5% of Titan Pharmaceuticals shares are held by institutional investors. 20.0% of BioCardia shares are held by company insiders. Comparatively, 24.9% of Titan Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Summary
Titan Pharmaceuticals beats BioCardia on 10 of the 15 factors compared between the two stocks.
Get Titan Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for TTNP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TTNP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Titan Pharmaceuticals Competitors List
Related Companies and Tools
Free TTNP Stock Alerts